Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (2): 263-265     DOI: 10.31083/j.rcm2202031
Special Issue: Pandemics and chronic diseases: short- and long-term treatment and management considerations
Editorial Previous articles | Next articles
COVID-19 infection and cardiometabolic complications: short- and long-term treatment and management considerations
Lee Stoner1, 2, *(), Mark Faghy2, 3, 4, Ryan Conners2, 5
1Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Healthy Living for Pandemic Event Protection (HL-PIVOT) Network, Chicago, IL 60612, USA
3Human Sciences Research Centre, University of Derby, DE22 1GB Derby, UK
4Department of Physical Therapy, College of Applied Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA
5Department of Kinesiology, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
Download:  PDF(169KB)  ( 602 ) Full text   ( 94 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
No abstract present.
Key words:  Lifestyle      COVID-19      Healthcare      Cardiometabolic      Cardiovascular      Underserved populations      Public health      Global health     
Submitted:  08 May 2021      Revised:  08 May 2021      Accepted:  19 May 2021      Published:  30 June 2021     
*Corresponding Author(s):  Lee Stoner     E-mail:  stonerl@email.unc.edu

Cite this article: 

Lee Stoner, Mark Faghy, Ryan Conners. COVID-19 infection and cardiometabolic complications: short- and long-term treatment and management considerations. Reviews in Cardiovascular Medicine, 2021, 22(2): 263-265.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2202031     OR     https://rcm.imrpress.com/EN/Y2021/V22/I2/263

[1] Peter A. McCullough, Raphael B. Stricker, Harvey A. Risch. Role of hydroxychloroquine in multidrug treatment of COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 545-546.
[2] Matteo Beltrami, Simone Bartolini, Massimo Milli, Alberto Palazzuoli. The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 677-690.
[3] Raffaele Galiero, Alfredo Caturano, Erica Vetrano, Arturo Cesaro, Luca Rinaldi, Teresa Salvatore, Raffaele Marfella, Celestino Sardu, Elisabetta Moscarella, Felice Gragnano, Paolo Calabrò, Ferdinando Carlo Sasso. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 755-768.
[4] Guinan Xie, An Yan, Peng Lin, Yi Wang, Liping Guo. Trimethylamine N-oxide—a marker for atherosclerotic vascular disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 787-797.
[5] Xiaoqing Zhu, Guanhua Xu, Wangyan Jin, Yingying Gu, Xuhua Huang, Lidan Ge. Apple or apple polyphenol consumption improves cardiovascular disease risk factors: a systematic review and meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 835-843.
[6] Niki Katsiki, Matina Kouvari, Demosthenes B Panagiotakos, Claudio Borghi, Christina Chrysohoou, Dimitri P Mikhailidis, Christos Pitsavos. The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 991-1001.
[7] Matthieu MILLION, Jean-Christophe LAGIER, Hervé TISSOT-DUPONT, Isabelle RAVAUX, Catherine DHIVER, Christelle TOMEI, Nadim CASSIR, Léa DELORME, Sébastien CORTAREDONA, Sophie AMRANE, Camille AUBRY, Karim BENDAMARDJI, Cyril BERENGER, Barbara DOUDIER, Sophie EDOUARD, Marie HOCQUART, Morgane MAILHE, Coralie PORCHETO, Piseth SENG, Catherine TRIQUET, Stéphanie GENTILE, Elisabeth JOUVE, Audrey GIRAUD-GATINEAU, Herve CHAUDET, Laurence CAMOIN-JAU, Philippe COLSON, Philippe GAUTRET, Pierre-Edouard FOURNIER, Baptiste MAILLE, Jean-Claude DEHARO, Paul HABERT, Jean-Yves GAUBERT, Alexis JACQUIER, Stéphane HONORE, Katell GUILLON-LORVELLEC, Yolande OBADIA, Philippe PAROLA, Philippe BROUQUI, Didier RAOULT. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 1063-1072.
[8] Janani Rangaswami. Closing gaps in the care of patients with heart-kidney disease: the time is now[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 257-258.
[9] Edoardo Pancaldi, Greta Pascariello, Giuliana Cimino, Angelica Cersosimo, Ludovica Amore, Fabio Alghisi, Nicola Bernardi, Emiliano Calvi, Carlo Mario Lombardi, Enrico Vizzardi, Marco Metra. Thrombotic risk in patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 277-286.
[10] Saeed Shoar, Waleed Ikram, Ahmed Ali Shah, Najam Farooq, Srikanth Gouni, Soheila Khavandi, Elsa Tabibzadeh, Siamak Khavandi. Non-high-density lipoprotein (non-HDL) cholesterol in adolescence as a predictor of atherosclerotic cardiovascular diseases in adulthood[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 295-299.
[11] Eyad Abuelgasim, Suleyman Shah, Biyaser Abuelgasim, Nikita Soni, Ashvin Thomas, Mustafa Elgasim, Amer Harky. Clinical overview of diabetes mellitus as a risk factor for cardiovascular death[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 301-314.
[12] Ibrahim AlShahrani, Jagadish Hosmani, Vidya Gurram Shankar, Abdulaziz AlShahrani, Rafi Ahmad Togoo, Syed M Yassin, Shahrukh Khan, Shankargouda Patil. COVID-19 and cardiovascular system—a comprehensive review[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 343-351.
[13] Agata Bielecka-Dabrowa, Anna Cichocka-Radwan, Joanna Lewek, Filip Pawliczak, Marek Maciejewski, Maciej Banach. Cardiac manifestations of COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 365-371.
[14] Paulino Alvarez, Alex Sianis, Jessica Brown, Abbas Ali, Alexandros Briasoulis. Chronic disease management in heart failure: focus on telemedicine and remote monitoring[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 403-413.
[15] Kui Huang, Xiao-Qin Wen, Ning Ren, Li Yang, Bo Gao. Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 461-467.
No Suggested Reading articles found!